UCAR T-cell therapy for myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental cell therapy (UCAR T-cells) that targets two markers on immune cells to treat myasthenia gravis that hasn't improved with standard treatments. It aims to reduce symptoms and improve daily functioning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Your myasthenia gravis symptoms haven't improved after at least 1 year of standard treatment (like immunosuppressants)
- You need regular plasma exchange or IVIG therapy to control your symptoms
- You have a score of 5 or more on a daily living questionnaire, and symptoms beyond just eye muscles
- You have adequate blood counts, liver function, and kidney function
- You agree to use effective birth control during and for 6 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using UCAR T-cells that target CD19 and BCMA proteins, for people with autoimmune diseases like lupus or arthritis that have come back or not responded to other treatments. It aims to see if this therapy can help control the disease.
This trial is testing a new type of cell therapy called CAR-T that targets two proteins (CD19 and BCMA) on certain immune cells. It aims to help people with severe myasthenia gravis that has not improved with standard treatments.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new cell therapy called anitocabtagene autoleucel (anito-cel) for people with generalized myasthenia gravis (gMG) that is not well controlled with current treatments. The goal is to see if it can reduce symptoms and improve quality of life.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.